Bio App Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 36

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 10

Bio App General Information

Description

Operator of a biotechnology company intended to offer a plant-derived genetically modified subunit vaccine for the prevention of swine fever. The company researches and develops plant-based green vaccine products for swine fever and African swine fever, as well as human medicines such as COVID-19, enabling doctors to prescribe biomedicine without any fear of side effects.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 394, Jigok-ro, Nam-gu
  • Pohang Techno Park Complex
  • Pohang, Gyeongsangbuk
  • South Korea
+82
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Vertical(s)
Corporate Office
  • 394, Jigok-ro, Nam-gu
  • Pohang Techno Park Complex
  • Pohang, Gyeongsangbuk
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bio App Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 01-Nov-2025 Completed Generating Revenue
6. Accelerator/Incubator 01-Jan-2024 Completed Generating Revenue
5. Reverse Merger 13-Jun-2025 Cancelled Generating Revenue
4. Later Stage VC (Series D) 20-Jul-2022 Completed Generating Revenue
3. Later Stage VC (Series C) 09-Aug-2020 Completed Generating Revenue
2. Later Stage VC (Series B) 16-Sep-2018 Completed Generating Revenue
1. Later Stage VC (Series A) 31-May-2017 Completed Generating Revenue
To view Bio App’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Bio App Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bio App Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
ECRUX Venture Partners Venture Capital Minority
Future Fit Asia Accelerator/Incubator
EcoPro Partners Corporate Venture Capital Minority
BNK Venture Capital Venture Capital Minority
CKD Venture Capital Corporate Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Bio App FAQs

  • When was Bio App founded?

    Bio App was founded in 2011.

  • Where is Bio App headquartered?

    Bio App is headquartered in Pohang, South Korea.

  • What is the size of Bio App?

    Bio App has 36 total employees.

  • What industry is Bio App in?

    Bio App’s primary industry is Biotechnology.

  • Is Bio App a private or public company?

    Bio App is a Private company.

  • What is Bio App’s current revenue?

    The current revenue for Bio App is .

  • How much funding has Bio App raised over time?

    Bio App has raised $3.84M.

  • Who are Bio App’s investors?

    ECRUX Venture Partners, Future Fit Asia, EcoPro Partners, BNK Venture Capital, and CKD Venture Capital are 5 of 10 investors who have invested in Bio App.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process